Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ELYMOTCMKTS:ETSTOTCMKTS:INTINASDAQ:KPTI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeELYMEliem Therapeutics$1.26-8.0%$1.25$2.35▼$11.55$37.49M-0.39486,688 shs204,220 shsETSTEarth Science Tech$0.12-16.7%$0.14$0.00▼$0.33$35.32M1.78101,800 shs93,079 shsINTIInhibitor Therapeutics$0.05-2.6%$0.05$0.03▼$0.10$8.37M-0.5335,307 shs24,250 shsKPTIKaryopharm Therapeutics$4.36-0.7%$5.08$3.51▼$17.40$37.67M0.2381,852 shs70,390 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceELYMEliem Therapeutics+2.24%+6.20%+15.13%+9.60%-83.47%ETSTEarth Science Tech+0.70%-4.00%-4.00%+10.77%-33.02%INTIInhibitor Therapeutics+8.26%-0.40%+13.18%-28.86%-28.96%KPTIKaryopharm Therapeutics-0.90%+1.15%-28.62%-36.74%-71.02%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationELYMEliem TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AETSTEarth Science TechN/AN/AN/AN/AN/AN/AN/AN/AINTIInhibitor TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AKPTIKaryopharm Therapeutics4.0372 of 5 stars3.51.00.04.62.22.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceELYMEliem Therapeutics 0.00N/AN/AN/AETSTEarth Science Tech 0.00N/AN/AN/AINTIInhibitor Therapeutics 0.00N/AN/AN/AKPTIKaryopharm Therapeutics 3.00Buy$43.20890.83% UpsideCurrent Analyst Ratings BreakdownLatest INTI, ELYM, KPTI, and ETST Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2025KPTIKaryopharm TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$34.00 ➝ $33.005/13/2025KPTIKaryopharm TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$5.00 ➝ $10.005/13/2025KPTIKaryopharm TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$54.00 ➝ $42.00(Data available from 6/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookELYMEliem TherapeuticsN/AN/AN/AN/A$3.90 per shareN/AETSTEarth Science Tech$11.95M2.96N/AN/A$0.01 per share12.00INTIInhibitor TherapeuticsN/AN/AN/AN/A$0.03 per shareN/AKPTIKaryopharm Therapeutics$142.13M0.27N/AN/A($1.47) per share-2.97Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateELYMEliem Therapeutics-$35.12M-$0.53N/A∞N/AN/A-47.03%-45.97%N/AETSTEarth Science Tech$810KN/A0.00∞N/AN/AN/AN/AN/AINTIInhibitor Therapeutics-$3.03M-$0.01N/A∞N/AN/A-70.65%-40.64%8/4/2025 (Estimated)KPTIKaryopharm Therapeutics-$143.10M-$13.26N/AN/AN/A-52.62%N/A-39.58%8/5/2025 (Estimated)Latest INTI, ELYM, KPTI, and ETST EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025KPTIKaryopharm Therapeutics-$4.21-$2.77+$1.44-$2.77$35.12 million$30.02 million3/28/2025Q4 2024INTIInhibitor TherapeuticsN/A-$0.01N/A-$0.01N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthELYMEliem TherapeuticsN/AN/AN/AN/AN/AETSTEarth Science TechN/AN/AN/AN/AN/AINTIInhibitor TherapeuticsN/AN/AN/AN/AN/AKPTIKaryopharm TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioELYMEliem TherapeuticsN/A60.4160.41ETSTEarth Science Tech0.010.871.09INTIInhibitor TherapeuticsN/A144.77144.77KPTIKaryopharm TherapeuticsN/A1.702.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipELYMEliem Therapeutics69.76%ETSTEarth Science TechN/AINTIInhibitor TherapeuticsN/AKPTIKaryopharm Therapeutics66.44%Insider OwnershipCompanyInsider OwnershipELYMEliem Therapeutics4.70%ETSTEarth Science Tech24.90%INTIInhibitor Therapeutics4.60%KPTIKaryopharm Therapeutics2.98%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableELYMEliem Therapeutics929.75 million28.35 millionNot OptionableETSTEarth Science Tech3294.30 million223.35 millionNot OptionableINTIInhibitor Therapeutics1172.57 million164.34 millionNot OptionableKPTIKaryopharm Therapeutics3808.64 million122.72 millionOptionableINTI, ELYM, KPTI, and ETST HeadlinesRecent News About These CompaniesBrokerages Set Karyopharm Therapeutics Inc. (NASDAQ:KPTI) PT at $43.20June 10 at 1:59 AM | americanbankingnews.comKaryopharm to Present at the Jefferies Global Healthcare ConferenceJune 3, 2025 | prnewswire.comKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 2, 2025 | prnewswire.comHere's Why Karyopharm Therapeutics (KPTI) Is a Great 'Buy the Bottom' Stock NowMay 26, 2025 | zacks.comDoes Karyopharm Therapeutics (KPTI) Have the Potential to Rally 521.62% as Wall Street Analysts Expect?May 19, 2025 | zacks.comKaryopharm to Participate at the 2025 RBC Capital Markets Global Healthcare ConferenceMay 19, 2025 | prnewswire.comRobert W. Baird Issues Pessimistic Forecast for Karyopharm Therapeutics (NASDAQ:KPTI) Stock PriceMay 15, 2025 | marketbeat.comKaryopharm Therapeutics (NASDAQ:KPTI) Posts Earnings Results, Beats Estimates By $1.44 EPSMay 14, 2025 | marketbeat.comKaryopharm Announces Poster Presentation on Selinexor in Myelofibrosis at the 2025 European Hematology Association Annual MeetingMay 14, 2025 | prnewswire.comKaryopharm Therapeutics (KPTI) Reports Q1 Loss, Lags Revenue EstimatesMay 12, 2025 | zacks.comKaryopharm Reports First Quarter 2025 Financial Results and Announces New Data in Myelofibrosis that Further Suggests Selinexor May Lead to Meaningful Spleen Volume Reduction, Symptom Improvement, Hemoglobin Stabilization and Disease ModificationMay 12, 2025 | prnewswire.comKaryopharm to Report First Quarter 2025 Financial Results on May 12, 2025May 8, 2025 | prnewswire.comWhy Karyopharm Therapeutics Inc.’s (KPTI) Stock Is Down 5.15%May 6, 2025 | aaii.comKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 1, 2025 | prnewswire.comKaryopharm Therapeutics Inc.DL-Exch. Notes 2018(25) BondMay 1, 2025 | markets.businessinsider.comWhy Karyopharm Therapeutics Inc.’s (KPTI) Stock Is Up 5.06%April 30, 2025 | aaii.comKaryopharm Therapeutics Inc. Common Stock (KPTI)April 23, 2025 | nasdaq.comKaryopharm Therapeutics Inc. Common Stock (KPTI)April 23, 2025 | nasdaq.comKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 1, 2025 | prnewswire.comKaryopharm price target lowered to split-adjusted $15 from $75 at Piper SandlerMarch 20, 2025 | markets.businessinsider.comKaryopharm Therapeutics (KPTI) Receives a Buy from Piper SandlerMarch 20, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingWhat Ray Dalio's Latest Moves Tell Investors By Gabriel Osorio-Mazilli | May 19, 2025View What Ray Dalio's Latest Moves Tell Investors Why Dollar General May Be Retail’s Most Undervalued ReboundBy Jeffrey Neal Johnson | June 2, 2025View Why Dollar General May Be Retail’s Most Undervalued ReboundINTI, ELYM, KPTI, and ETST Company DescriptionsEliem Therapeutics NASDAQ:ELYM$1.26 -0.11 (-8.03%) As of 06/11/2025Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.Earth Science Tech OTCMKTS:ETST$0.12 -0.02 (-16.67%) As of 11:33 AM EasternEarth Science Tech, Inc. focuses on health and wellness industry. It operates men's health telemedicine platform under brand Peak name; and operates pharmacy. The company offers supplements and topicals products. The company was formerly known as Ultimate Novelty Sports, Inc. and changed its name to Earth Science Tech, Inc. in March 2014. Earth Science Tech, Inc. was incorporated in 2010 and is headquartered in Miami, Florida.Inhibitor Therapeutics OTCMKTS:INTI$0.05 0.00 (-2.61%) As of 12:57 PM EasternInhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. It has license agreement with Johns Hopkins University. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida. Inhibitor Therapeutics, Inc operates as a subsidiary of Mayne Pharma Ventures Pty Ltd.Karyopharm Therapeutics NASDAQ:KPTI$4.36 -0.03 (-0.68%) As of 04:00 PM EasternKaryopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ignore the Noise—Samsara Stock Is Still a Strong Buy Oracle’s Cloud Boom Is Just Getting Started Netflix Sets New Highs—Price Targets Keep Climbing IonQ’s $1B Acquisition and Drug Discovery Leap With NVIDIA Alibaba’s Dip Is a Gift—Here’s the Price That Matters Betting on Disruption: Is Lemonade the Future of Insurance? Starbucks Stock: Culture Fix May Be Key to Long-Term Growth GameStop Turns a Profit, But Core Business Keeps Shrinking Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
